Loading...

VKTX VIKING THERAPEUTICS INC US FDA Inspections 8-K Filing

VKNG

VKTX

VIKING THERAPEUTICS INC

(VKTX)

2025 8-K

Financial Results Report

Quarterly Results

Trial Results Update

Financial Statements

Financial Statements

Supply Agreement

Clinical Trial Results

Q3 Financial Results

Earnings Reports

Results Announcement

Annual Meeting Approval

Earnings Reports

Clinical Trial Results

Underwriting Agreement for ...

Earnings Reports

Earnings Reports

Earnings Reports

Annual Meeting of Stockholders

Bylaw Amendment

Earnings Reports

Underwriting Agreement for ...

Clinical Study Initiation

Clinical Trial Results

Earnings Report

External Links:

On August 19, 2025, Viking Therapeutics, Inc. announced the top-line results from its Phase 2 clinical trial of the VK2735 oral tablet formulation. This event signifies a significant development for the company.

AI Assistant

VIKING THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.